Medicine and Dentistry
Nodular Melanoma
100%
Progression Free Survival
100%
Nivolumab
100%
Ipilimumab
100%
Cytokine
42%
Pembrolizumab
42%
Tumor Necrosis Factor
28%
Programmed Death-Ligand 1
28%
Immunotherapy
28%
Biological Marker
14%
Long Term Survival
14%
Treatment Response
14%
Metastatic Melanoma
14%
Liquid Biopsy
14%
Inflammatory Cytokine
14%
Pharmacology, Toxicology and Pharmaceutical Science
Melanoma
100%
Progression Free Survival
100%
Nivolumab
100%
Ipilimumab
100%
Cytokine
57%
Pembrolizumab
42%
Tumor Necrosis Factor
28%
Immunotherapy
28%
Biological Marker
14%
Long Term Survival
14%
Metastatic Melanoma
14%
Neuroscience
Ipilimumab
100%
Nivolumab
100%
Lambrolizumab
75%
CXCL5
75%
CXCL10
50%
Immunotherapy
50%
CCL20
25%
Keyphrases
Soluble PD-L1 (sPD-L1)
100%
Nivolumab Plus Ipilimumab
100%
CXCL5
42%
Approximation Analysis
14%
Unsupervised Machine Learning Approach
14%
Projection Analysis
14%
Immunology and Microbiology
CXCL5
42%
Unsupervised Machine Learning
14%